文献速递膀胱癌与上尿路尿路上皮癌

临床T2N0肌层浸润性膀胱癌的新辅助化疗或免疫治疗:是时候改变范式了吗?

Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?
PubMed 文献 · Eur Urol Oncol · 2020-08-23

本文通过一例41岁女性临床T2N0M0肌层浸润性膀胱癌患者参加PURE-01二期试验的病例,探讨新辅助免疫治疗作为非局部晚期肌层浸润性膀胱癌一线治疗的潜力。患者接受3周期帕博利珠单抗新辅助治疗后行机器人辅助根治性膀胱切除术,病理达完全缓解(ypT0ypN0)。提示新辅助免疫治疗可能优于传统化疗,但需进一步研究支持。

要点

  • 临床T2N0肌层浸润性膀胱癌患者可考虑新辅助免疫治疗。
  • 帕博利珠单抗新辅助治疗后可达病理完全缓解。
  • 免疫相关不良事件如甲状腺功能减退可管理。

核心结论

  • 越来越多证据表明,对于非局部晚期肌层浸润性膀胱癌(cT2N0),一线新辅助免疫治疗可能有益且缺点少于传统化疗。

研究设计与样本

  • 本文为一例病例报告,患者为41岁健康绝经前女性,临床T2N0M0肌层浸润性膀胱癌,入组PURE-01二期试验(NCT02736266)。

主要发现

  • 患者接受3周期新辅助帕博利珠单抗(200mg)每3周一次后行机器人辅助根治性膀胱切除术加扩大盆腔淋巴结清扫,病理完全缓解(ypT0ypN0)。
  • 治疗后唯一相关永久性免疫介导不良事件为自身免疫性甲状腺炎继发甲状腺功能减退,术后2个月出现,激素替代治疗成功管理。
  • 治疗后2年患者无症状且无疾病复发。

关键数值与推荐

  • PD-L1联合阳性分数为84%,肿瘤突变负荷为16.67 mut/Mb。
  • 基因组分析(FoundationONE)显示TP53、EZH2、APC、TERT、CDKN1A、CDKN1B、ARID1A基因体细胞突变及BRCA2基因截断。

临床怎么用

  • 对于临床T2N0肌层浸润性膀胱癌,新辅助免疫治疗可作为潜在治疗选择,但需在临床试验背景下进行。
  • 治疗前应评估生物标志物如PD-L1表达和肿瘤突变负荷,并利用影像学策略评估治疗反应。

局限性

  • 本文为单一病例报告,证据级别有限,需进一步研究支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 41-yr-old, otherwise healthy, premenopausal woman presented at our uro-oncology clinic with a diagnosis of muscle-invasive bladder cancer following a transurethral resection of the bladder performed at another center. After a thorough discussion with the patient, she was enrolled in the phase II PURE-01 trial (NCT02736266), testing three cycles of neoadjuvant pembrolizumab (200mg) every 3 wk before radical cystectomy. Before treatment, imaging studies were obtained as per the protocol using computed tomography (CT), [18F]fluorodeoxyglucose positron emission tomography/CT, and multiparametric magnetic resonance imaging of the bladder, defining a clinically localized T2N0M0 stage. As per the protocol, potential biomarkers were assessed, including PD-L1 expression (84% combined positive score), tumor mutational burden (16.67 mut/Mb), and genomic profiling (FoundationONE assay; somatic mutation in TP53, EZH2, APC, TERT, CDKN1A, CDKN1B, and ARID1A genes, and truncation in BRCA2 gene). After immunotherapy, the patient underwent a robot-assisted radical cystectomy with extended pelvic lymph node dissection. The final pathology report revealed absence of residual disease (ie, pathological complete response, ypT0ypN0). During follow-up, the only relevant and permanent immune-mediated adverse event was hypothyroidism secondary to an autoimmune thyroiditis. It appeared 2 mo after radical cystectomy and it was managed successfully with hormonal replacement therapy. Two years after treatment, the patient is asymptomatic and free from disease recurrence. PATIENT SUMMARY: Increasing evidence suggests that frontline neoadjuvant immunotherapy may be beneficial for patients diagnosed with non-locally advanced, muscle-invasive bladder cancer (cT2N0), with fewer drawbacks than traditional chemotherapy. Although further studies are needed in support, this vision opens the opportunity for future clinical trials testing the potential incremental benefits of immunotherapy and the utility of novel biomarker- and imaging-based strategies to assess response to therapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Pederzoli F, Bandini M, Marandino L, et al. Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? Eur Urol Oncol. 2020. PMID: 32847746. doi:10.1016/j.euo.2020.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。